T2 Biosystems, Inc. (NASDAQ:TTOO – Get Free Report) was the target of a large growth in short interest in the month of November. As of November 15th, there was short interest totalling 1,020,000 shares, a growth of 22.2% from the October 31st total of 834,800 shares. Approximately 14.7% of the company’s stock are sold short. Based on an average daily volume of 581,500 shares, the days-to-cover ratio is presently 1.8 days.
Analysts Set New Price Targets
Separately, StockNews.com began coverage on T2 Biosystems in a research note on Monday, November 25th. They issued a “sell” rating on the stock.
View Our Latest Stock Report on T2 Biosystems
T2 Biosystems Trading Up 14.9 %
Institutional Investors Weigh In On T2 Biosystems
A hedge fund recently raised its stake in T2 Biosystems stock. Virtu Financial LLC boosted its holdings in T2 Biosystems, Inc. (NASDAQ:TTOO – Free Report) by 29.9% during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 13,096 shares of the medical equipment provider’s stock after acquiring an additional 3,018 shares during the period. Virtu Financial LLC owned 0.24% of T2 Biosystems worth $39,000 as of its most recent filing with the Securities and Exchange Commission. 23.18% of the stock is currently owned by institutional investors.
T2 Biosystems Company Profile
T2 Biosystems, Inc, an in vitro diagnostics company, develops and sells diagnostic products and product candidates in the United States and internationally. Its technology enables detection of pathogens, biomarkers, and other abnormalities in various unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum, cerebral spinal fluid, and urine.
Featured Stories
- Five stocks we like better than T2 Biosystems
- How to Plot Fibonacci Price Inflection Levels
- ServiceNow: Will the High-Flyer Finally Split in 2024?
- CD Calculator: Certificate of Deposit Calculator
- MarketBeat Week in Review – 11/25 – 11/29
- 3 Warren Buffett Stocks to Buy Now
- These 3 Stocks Are Heavy Hitters in Alternative Asset Management
Receive News & Ratings for T2 Biosystems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for T2 Biosystems and related companies with MarketBeat.com's FREE daily email newsletter.